The therapeutic effect of B‐type natriuretic peptides in acute decompensated heart failure

• Published in: Clinical and experimental pharmacology & physiology Vol. 47; no. 7; pp. 1120 - 1133
• Main Authors: Caprnda, Martin, Zulli, Anthony, Shiwani, Haaris A., Kubatka, Peter, Filipova, Slavomira, Valentova, Vanda, Gazdikova, Katarina, Mozos, Ioana, Berukstis, Andrius, Laucevicius, Aleksandras, Rihacek, Ivan, Dragasek, Jozef, Prosecky, Robert, Egom, Emmanuel E., Staffa, Robert, Kruzliak, Peter, Krasnik, Vladimir
• Format: Journal Article
• Language: English
• Published: Australia Wiley Subscription Services, Inc 01.07.2020
• Subjects: Acute Disease; Animals; B‐type natriuretic peptide; clinical effectiveness; Clinical trials; Congestive heart failure; Diuresis; Heart failure; Heart Failure - blood; Heart Failure - drug therapy; Heart Failure - physiopathology; Humans; Natriuretic Peptide, Brain - blood; Natriuretic Peptide, Brain - therapeutic use; Peptides; pharmacotherapy; Renal function; clinical effectiveness; heart failure; B-type natriuretic peptide; pharmacotherapy
• ISSN: 0305-1870; 1440-1681; 1440-1681
• DOI: 10.1111/1440-1681.13290

B‐type natriuretic peptide (BNP) exhibits roles in natriuresis and diuresis, making it an ideal drug that may aid in diuresing a fluid‐overloaded patient with poor or worsening renal function. Several randomized clinical trials have tested the hypothesis that infusions of pharmacological doses of BNP to acute heart failure (HF) patients may enhance decongestion and preserve renal function in this clinical setting. Unfortunately, none of these have demonstrated beneficial outcomes. The current challenge for BNP research in acute HF lies in addressing a failure of concept and a reluctance to abandon an ineffective research model. Future success will necessitate a detailed understanding of the mechanism of action of BNP, as well as better integration of basic and clinical science.